Cargando…
Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study
Background: Histamine Intolerance (HIT) is a multifaceted pseudoallergic disorder possibly due to defective histamine metabolism. Diamine oxidase (DAO) contributes to histamine degradation and can be measured in the serum. The role of DAO measurement in the diagnostic work-up of HIT still remains un...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003468/ https://www.ncbi.nlm.nih.gov/pubmed/35406126 http://dx.doi.org/10.3390/nu14071513 |
_version_ | 1784686141468835840 |
---|---|
author | Cucca, Valentina Ramirez, Giuseppe A. Pignatti, Patrizia Asperti, Chiara Russo, Marco Della-Torre, Emanuel Breda, Daniela Burastero, Samuele E. Dagna, Lorenzo Yacoub, Mona-Rita |
author_facet | Cucca, Valentina Ramirez, Giuseppe A. Pignatti, Patrizia Asperti, Chiara Russo, Marco Della-Torre, Emanuel Breda, Daniela Burastero, Samuele E. Dagna, Lorenzo Yacoub, Mona-Rita |
author_sort | Cucca, Valentina |
collection | PubMed |
description | Background: Histamine Intolerance (HIT) is a multifaceted pseudoallergic disorder possibly due to defective histamine metabolism. Diamine oxidase (DAO) contributes to histamine degradation and can be measured in the serum. The role of DAO measurement in the diagnostic work-up of HIT still remains unclear, and conflicting results have been reported in the literature. Therefore, we aimed to evaluate the possible clinical usefulness and consistency of DAO value ranges as provided by the assay manufacturer and verify whether they could predict the response to treatment. Methods: We retrospectively analyzed 192 outpatients with HIT symptoms and measured serum DAO values at baseline. Patients were prescribed either with low-histamine diet and/or enzymatic supplementation according to symptom severity and re-evaluated six to eight months later. Patients were stratified into three groups according to DAO levels: <3 U/mL, 3–10 U/mL, and >10 U/mL. HIT severity was assessed on a scale of 1 to 5 before and after treatment. Results: A total of 146 patients completed the study. Gastrointestinal and cutaneous symptoms, often associated with headache, were more frequent in subjects with DAO < 10 U/mL. Symptom severity and DAO ranges were correlated. Patients with intermediate DAO levels (3–10 U/mL) showed a more complex clinical phenotype but also a more significant improvement in symptom severity (score reduction 50%, interquartile range (IQR) = 33–60%) when compared to patients with low DAO (40%, IQR = 20–60%; p = 0.045) or high DAO (33%, IQR = 0–50%; p < 0.001). Complex clinical phenotypes were also more frequent in patients with intermediate DAO levels. Conclusions: HIT is characterized by typical symptoms and low levels of DAO activity. Symptom severity was associated with the degree of DAO deficiency. Patients with DAO values between 3 and 10 U/mL show the best response to treatment (low-histamine diet and/or DAO supplementation). DAO value could arguably be considered as a predictor of clinical response to treatment. Prospective studies are needed to confirm these data. |
format | Online Article Text |
id | pubmed-9003468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90034682022-04-13 Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study Cucca, Valentina Ramirez, Giuseppe A. Pignatti, Patrizia Asperti, Chiara Russo, Marco Della-Torre, Emanuel Breda, Daniela Burastero, Samuele E. Dagna, Lorenzo Yacoub, Mona-Rita Nutrients Article Background: Histamine Intolerance (HIT) is a multifaceted pseudoallergic disorder possibly due to defective histamine metabolism. Diamine oxidase (DAO) contributes to histamine degradation and can be measured in the serum. The role of DAO measurement in the diagnostic work-up of HIT still remains unclear, and conflicting results have been reported in the literature. Therefore, we aimed to evaluate the possible clinical usefulness and consistency of DAO value ranges as provided by the assay manufacturer and verify whether they could predict the response to treatment. Methods: We retrospectively analyzed 192 outpatients with HIT symptoms and measured serum DAO values at baseline. Patients were prescribed either with low-histamine diet and/or enzymatic supplementation according to symptom severity and re-evaluated six to eight months later. Patients were stratified into three groups according to DAO levels: <3 U/mL, 3–10 U/mL, and >10 U/mL. HIT severity was assessed on a scale of 1 to 5 before and after treatment. Results: A total of 146 patients completed the study. Gastrointestinal and cutaneous symptoms, often associated with headache, were more frequent in subjects with DAO < 10 U/mL. Symptom severity and DAO ranges were correlated. Patients with intermediate DAO levels (3–10 U/mL) showed a more complex clinical phenotype but also a more significant improvement in symptom severity (score reduction 50%, interquartile range (IQR) = 33–60%) when compared to patients with low DAO (40%, IQR = 20–60%; p = 0.045) or high DAO (33%, IQR = 0–50%; p < 0.001). Complex clinical phenotypes were also more frequent in patients with intermediate DAO levels. Conclusions: HIT is characterized by typical symptoms and low levels of DAO activity. Symptom severity was associated with the degree of DAO deficiency. Patients with DAO values between 3 and 10 U/mL show the best response to treatment (low-histamine diet and/or DAO supplementation). DAO value could arguably be considered as a predictor of clinical response to treatment. Prospective studies are needed to confirm these data. MDPI 2022-04-05 /pmc/articles/PMC9003468/ /pubmed/35406126 http://dx.doi.org/10.3390/nu14071513 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cucca, Valentina Ramirez, Giuseppe A. Pignatti, Patrizia Asperti, Chiara Russo, Marco Della-Torre, Emanuel Breda, Daniela Burastero, Samuele E. Dagna, Lorenzo Yacoub, Mona-Rita Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title | Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title_full | Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title_fullStr | Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title_full_unstemmed | Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title_short | Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study |
title_sort | basal serum diamine oxidase levels as a biomarker of histamine intolerance: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003468/ https://www.ncbi.nlm.nih.gov/pubmed/35406126 http://dx.doi.org/10.3390/nu14071513 |
work_keys_str_mv | AT cuccavalentina basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT ramirezgiuseppea basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT pignattipatrizia basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT aspertichiara basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT russomarco basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT dellatorreemanuel basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT bredadaniela basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT burasterosamuelee basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT dagnalorenzo basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy AT yacoubmonarita basalserumdiamineoxidaselevelsasabiomarkerofhistamineintolerancearetrospectivecohortstudy |